Immune-Evasive NIR-II Nanoplatforms for Repeatable Photodynamic Therapy.

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Photochemistry

Background:

• Photodynamic therapy (PDT) is limited by oxygen dependency, heat generation, and immune clearance during repeated treatments.
• Existing PDT strategies face challenges in clinical translation due to systemic toxicity and reduced efficacy over time.

Purpose of the Study:

• To develop a next-generation, immune-evasive photodynamic nanoplatform for sustainable and precise PDT.
• To engineer a system that overcomes oxygen dependence and minimizes immune clearance for enhanced therapeutic outcomes.

Main Methods:

• Synthesized KD1-loaded hyaluronic acid-poly(ethylene glycol) nanoparticles (KD1@HPEG NPs) utilizing Type I photochemistry.
• Incorporated a thiopyrylium photosensitizer (KD1) with specific substituents to enhance intersystem crossing and ROS generation.
• Engineered stealth surface properties to evade immune clearance and improve tumor targeting.

Main Results:

• KD1@HPEG NPs demonstrated efficient Type I reactive oxygen species (ROS) generation with negligible heat release.
• The nanoparticles exhibited oxygen-independent ROS production and sustained near-infrared II (NIR-II) fluorescence imaging.
• The platform showed preserved therapeutic efficacy under repeated dosing, circumventing accelerated blood clearance.

Conclusions:

• KD1@HPEG NPs represent a generalizable strategy for long-term, immune-tolerant photodynamic therapy.
• This nanoplatform offers a clinically viable approach for durable, precision phototheranostics with enhanced safety and efficacy.